Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

Inclusion Criteria: * Male and/or female patients below 85 years of age (inclusive) * Diagnosis of mild Alzheimer's Disease * Mini-Mental State Examination (MMSE) 20 to 26 (inclusive) at screening, untreated or on stable dose of cholinesterase inhibitor or memantine over the last 4 weeks prior to clinical assessments Exclusion Criteria: * Previously participated in an AD vaccine study and received active treatment * History or presence of an active autoimmune disease * History or presence of seizure disorder * Presence of significant coronary heart disease and/or cerebrovascular disease * Presence of other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression) * Advanced, severe, progressive or unstable disease that might interfere with the safety, tolerability and pharmacodynamic assessments of the patient Other protocol-defined inclusion/exclusion criteria may apply